SUMMARY
# NLRP3 Inflammasome Validation Study in Parkinson's Disease
## Background and Rationale
# NLRP3 Inflammasome Validation Study in Parkinson's Disease
Parkinson's disease represents a significant neurodegenerative challenge characterized by progressive loss of dopaminergic neurons in the substantia nigra pars compacta. While genetic mutations account for only 5-10% of cases, emerging evidence suggests that neuroinflammation plays a critical role in the pathogenesis of both familial and sporadic
METHODOLOGY NOTES
**Phase 1: Patient Recruitment and Characterization (Months 1-6)**
• Recruit 120 PD patients (Hoehn & Yahr stages 1-3) and 60 age-matched healthy controls
• Obtain informed consent and perform comprehensive clinical assessments (UPDRS-III, MoCA, Schwab & England ADL)
• Collect demographic data, medication history, and disease duration
• Perform DaTscan imaging to confirm dopaminergic deficit in PD patients
• Exclude patients with atypical parkinsonism, dementia (MoCA <24), or immunosuppressive therapy
**Phase 2: Biospecimen Collection and Processing (Months 2-8)**
• Collect fasting blood samples (30ml) and CSF via lumbar puncture (15ml) from all participants
• Isolate peripheral blood mononuclear cells (PBMCs) using Ficoll density gradient centrifugation
• Process CSF samples within 2 hours, aliquot and store at -80°C
• Extract RNA and protein from PBMCs for inflammasome analysis
• Perform flow cytometry on fresh PBMCs within 4 hours of collection
**Phase 3: NLRP3 Inflammasome Activi